The efficacy and safety of KRD and KD regimens for multiple myeloma patients:Retrospective study by Kansai Myeloma Forum - The efficacy and safety of KRD and KD regimens for MM patients:Retrospective study by KMF

111 patients received KRd. The median progression-free survival (PFS) was 9.7 months. Multivariate analysis showed that reduction of the carfilzomib dose and non-IgG M protein significantly affected PFS. 50 patients received Kd. The median PFS was 7.1 months. Based on the multivariate analysis, reduction of the carfilzomib dose and ISSIII significantly affected PFS. Our analysis showed that an adequate dose of carfilzomib is important for achieving the best survival benefits in a real-world setting.